Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Legend Biotech Corporation is a biotechnology business based in the US. Legend Biotech Corporation shares (LEGN) are listed on the NASDAQ and all prices are listed in US Dollars. Legend Biotech Corporation employs 900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$52.27|
|52-week range||$23.41 - $58.00|
|50-day moving average||$47.86|
|200-day moving average||$39.84|
|Wall St. target price||$58.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-3.99%|
|1 month (2021-09-27)||11.24%|
|3 months (2021-07-27)||25.50%|
|6 months (2021-04-27)||74.12%|
|1 year (2020-10-27)||87.41%|
|2 years (2019-10-23)||N/A|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Revenue TTM||$88.9 million|
|Gross profit TTM||$78.7 million|
|Return on assets TTM||-22.17%|
|Return on equity TTM||-80.13%|
|Market capitalisation||$7.7 billion|
TTM: trailing 12 months
There are currently 1.5 million Legend Biotech Corporation shares held short by investors – that's known as Legend Biotech Corporation's "short interest". This figure is 16.4% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Legend Biotech Corporation shares can be evaluated.
Legend Biotech Corporation's "short interest ratio" (SIR) is the quantity of Legend Biotech Corporation shares currently shorted divided by the average quantity of Legend Biotech Corporation shares traded daily (recently around 383552.14105793). Legend Biotech Corporation's SIR currently stands at 3.97. In other words for every 100,000 Legend Biotech Corporation shares traded daily on the market, roughly 3970 shares are currently held short.
However Legend Biotech Corporation's short interest can also be evaluated against the total number of Legend Biotech Corporation shares, or, against the total number of tradable Legend Biotech Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Legend Biotech Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Legend Biotech Corporation shares in existence, roughly 10 shares are currently held short) or 0.0464% of the tradable shares (for every 100,000 tradable Legend Biotech Corporation shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Legend Biotech Corporation.
Find out more about how you can short Legend Biotech Corporation stock.
We're not expecting Legend Biotech Corporation to pay a dividend over the next 12 months.
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.